| pubmed-article:12515900 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:12515900 | lifeskim:mentions | umls-concept:C0002395 | lld:lifeskim |
| pubmed-article:12515900 | lifeskim:mentions | umls-concept:C0014361 | lld:lifeskim |
| pubmed-article:12515900 | lifeskim:mentions | umls-concept:C1948041 | lld:lifeskim |
| pubmed-article:12515900 | lifeskim:mentions | umls-concept:C0302350 | lld:lifeskim |
| pubmed-article:12515900 | lifeskim:mentions | umls-concept:C1521840 | lld:lifeskim |
| pubmed-article:12515900 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:12515900 | pubmed:dateCreated | 2003-3-24 | lld:pubmed |
| pubmed-article:12515900 | pubmed:abstractText | Glucagon-like peptide-1 (7-36)-amide (GLP-1) is an insulinotropic hormone, secreted from the enteroendocrine L cells of the intestinal tract in response to nutrient ingestion. It enhances pancreatic islet beta-cell proliferation and glucose-dependent insulin secretion, and lowers blood glucose in patients with type 2 diabetes mellitus. GLP-1 receptors, which are coupled to the cyclic AMP second messenger pathway, are expressed throughout the brains of rodents and humans. The chemoarchitecture of receptor distribution in the brain correlates well with a central role for GLP-1 in the regulation of food intake and response to aversive stress. We have recently reported that GLP-1 and several longer acting analogs that bind at the GLP-1 receptor, possess neurotrophic properties, and offer protection against glutamate-induced apoptosis and oxidative injury in cultured neuronal cells. Furthermore, GLP-1 can modify processing of the amyloid beta- protein precursor in cell culture and dose-dependently reduces amyloid beta-peptide levels in the brain in vivo. As such, this review discusses the known role of GLP-1 within the central nervous system, and considers the potential of GLP-1 and analogs as novel therapeutic targets for intervention in Alzheimer's disease (AD) and potentially other central and peripheral neurodegenerative conditions. | lld:pubmed |
| pubmed-article:12515900 | pubmed:language | eng | lld:pubmed |
| pubmed-article:12515900 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12515900 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:12515900 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12515900 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12515900 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12515900 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12515900 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12515900 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12515900 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12515900 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12515900 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:12515900 | pubmed:month | Dec | lld:pubmed |
| pubmed-article:12515900 | pubmed:issn | 1387-2877 | lld:pubmed |
| pubmed-article:12515900 | pubmed:author | pubmed-author:PerryTracyAnn... | lld:pubmed |
| pubmed-article:12515900 | pubmed:author | pubmed-author:GreigNigel... | lld:pubmed |
| pubmed-article:12515900 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:12515900 | pubmed:volume | 4 | lld:pubmed |
| pubmed-article:12515900 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:12515900 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:12515900 | pubmed:pagination | 487-96 | lld:pubmed |
| pubmed-article:12515900 | pubmed:dateRevised | 2005-11-17 | lld:pubmed |
| pubmed-article:12515900 | pubmed:meshHeading | pubmed-meshheading:12515900... | lld:pubmed |
| pubmed-article:12515900 | pubmed:meshHeading | pubmed-meshheading:12515900... | lld:pubmed |
| pubmed-article:12515900 | pubmed:meshHeading | pubmed-meshheading:12515900... | lld:pubmed |
| pubmed-article:12515900 | pubmed:meshHeading | pubmed-meshheading:12515900... | lld:pubmed |
| pubmed-article:12515900 | pubmed:meshHeading | pubmed-meshheading:12515900... | lld:pubmed |
| pubmed-article:12515900 | pubmed:meshHeading | pubmed-meshheading:12515900... | lld:pubmed |
| pubmed-article:12515900 | pubmed:meshHeading | pubmed-meshheading:12515900... | lld:pubmed |
| pubmed-article:12515900 | pubmed:meshHeading | pubmed-meshheading:12515900... | lld:pubmed |
| pubmed-article:12515900 | pubmed:meshHeading | pubmed-meshheading:12515900... | lld:pubmed |
| pubmed-article:12515900 | pubmed:meshHeading | pubmed-meshheading:12515900... | lld:pubmed |
| pubmed-article:12515900 | pubmed:meshHeading | pubmed-meshheading:12515900... | lld:pubmed |
| pubmed-article:12515900 | pubmed:meshHeading | pubmed-meshheading:12515900... | lld:pubmed |
| pubmed-article:12515900 | pubmed:meshHeading | pubmed-meshheading:12515900... | lld:pubmed |
| pubmed-article:12515900 | pubmed:year | 2002 | lld:pubmed |
| pubmed-article:12515900 | pubmed:articleTitle | The glucagon-like peptides: a new genre in therapeutic targets for intervention in Alzheimer's disease. | lld:pubmed |
| pubmed-article:12515900 | pubmed:affiliation | Laboratory of Neuroscience, Section of Drug Design & Development, Gerontology Research Center, National Institute on Aging, National Institutes of Health, 5600 Nathan Shock Drive, Baltimore, MD 21224, USA. perryt@grc.nih.gov | lld:pubmed |
| pubmed-article:12515900 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:12515900 | pubmed:publicationType | Review | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12515900 | lld:pubmed |
